FMC's Hail Mary: Asset Sales, a New Product Wave, and a Bet on Brazil
A company in transition
FMC Corporation is in the midst of a profound transformation. The stock has collapsed 92% from its 2022 peak, and the last 90 days alone have wiped out another 37%. The company is carrying roughly $4.1 billion in net debt against a collapsing earnings base, and its growth portfolio — once the answer to every question — now shares the stage with a fire sale of assets and a strategic review that could end in a full disposal.
On the Q1 2026 call, management struck a tone of controlled urgency. “We are in late stages with several potential buyers and expect to sign a definitive agreement in May” — Pierre Brondeau, Chairman, Chief Executive Officer and President · 2026-07-30 for the India business, and “in advanced discussions with multiple potential partners regarding licensing of one of our new active ingredients.” — Pierre Brondeau, Chairman, Chief Executive Officer and President · 2026-07-30 The goal: roughly $1 billion in debt paydown this year, with about $700 million already in advanced negotiations.
The Rynaxypyr pivot and the growth portfolio
The core challenge remains Rynaxypyr, the once-blockbuster insecticide now facing generic erosion. Partner sales are set to fall from $200 million to under $100 million this year, while the branded strategy aims to hold earnings flat via a mix shift toward high-load and advanced formulations. “We are forecasting $700 million of Rynaxypyr sales... partner sales decreasing to a number lower than $100 million,” Pierre Brondeau explained, adding that “the volume gain, the improved mix... and the cost reduction compensate for the lower price.”
Meanwhile, the brand Rynaxypyr is being repositioned to compete against generics, with early signs of share gains from other insecticide classes. But the real hope lies in the non diamide core and the new active ingredients — Isoflex, fluindapyr, and Dodhylex. Isoflex just received EU approval, the first new herbicide in the EU since 2019, potentially opening more than 55 million planted hectares. This is the engine for second-half growth, with the company expecting $175-200 million in incremental sales from new products.
Debt, covenants, and the sale of everything
The balance sheet is the immediate driver. First-quarter gross debt rose to $4.5 billion, and net debt to $4.1 billion. The revolver was amended to a fully secured basis, adding a secured leverage covenant at 3.5x. “We intend to go to market this quarter with a secured high-yield bond offering to redeem $500 million of notes that mature in October,” — Andrew Sandifer, Executive Vice President and Chief Financial Officer · 2026-07-30 said CFO Andrew Sandifer.
The strategic alternatives review, announced in February, is progressing. Pierre affirmed, “multiple options are being evaluated,” and he later noted that “there are 2 different ways to think about licensing” — either broad molecule licensing for pre-commercial assets or product-level licenses for registered molecules. The company is also selling noncore molecules and real estate via sale-leasebacks.
This is a company trying to shore up its balance sheet while simultaneously considering a sale. That tension is the story: the operational turnaround is real, but the financial distress is real too.
Outlook: Brazil, tariffs, and the second-half bet
Management is doubling down on the second half. “our forecast in H2 at the midpoint is about $425 million of sales improvement in H2 versus H1,” — Pierre Brondeau, Chairman, Chief Executive Officer and President · 2026-07-30 with the bulk coming from direct sales in Brazil, new products, and seasonality. By end-June, they expect orders representing half of H2 direct sales in Brazil.
Tariffs and the Iran conflict add uncertainty. “There is 2 types of tariffs which we have paid... those which have been liquidated... and those which have not been liquidated... those seem to have a higher probability to be collected faster.” — Pierre Brondeau, Chairman, Chief Executive Officer and President · 2026-07-30 The company has not factored in any tariff refunds yet, but a global wave of refunds is hitting peers (e.g., Apple, Baxter).
Prior calls had similar themes. In the April call, we heard: “we are expecting to close on the India deal in the month of May,” — Pierre Brondeau, Chairman, Chief Executive Officer and President · 2026-04-30 and “the #1 criteria is how we are going to be performing in growing the percentage of sales on the high-end part.” — Pierre Brondeau, Chairman, Chief Executive Officer and President · 2026-04-30
The numbers back the rhetoric. Effective Net Cash now stands at -$4.1B, while revenue remains 30% below its 2022 peak. Gross margin has fallen to 32.5%, down 7.5pp year-over-year. The company is running on hope and a $1B asset-sale plan.
Based on the actions we are taking, I believe the first half will represent an earnings trough for the business with higher sequential earnings in the second half of this year, followed by improved full year results in '27 and 2028.
That’s a high hurdle. The stock is priced for failure, but if the Brazil ramp and new molecules deliver, there could be a mean-reversion trade. For now, FMC is a macro-wreck with a micro-beat waiting to happen.